Published in Proc Natl Acad Sci U S A on December 15, 2003
The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci U S A (2006) 1.96
Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis (2004) 1.86
High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem Biol (2007) 1.85
The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis (2011) 1.72
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem (2007) 1.58
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem (2007) 1.53
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med (2009) 1.49
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol (2008) 1.42
Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration. Physiol Rev (2014) 1.32
Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci U S A (2007) 1.31
Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev Technol (2011) 1.28
The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther (2009) 1.18
The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther (2009) 1.17
Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proc Natl Acad Sci U S A (2004) 1.13
Screening for pharmacological chaperones in Fabry disease. Biochem Biophys Res Commun (2007) 1.11
α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants. J Biol Chem (2012) 1.02
Pharmacological chaperone therapy for Fabry disease. Proc Jpn Acad Ser B Phys Biol Sci (2012) 1.00
Emerging therapies for neurodegenerative lysosomal storage disorders - from concept to reality. J Inherit Metab Dis (2011) 0.99
Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect Medicin Chem (2009) 0.96
Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity. Antimicrob Agents Chemother (2008) 0.95
Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease. EBioMedicine (2016) 0.93
Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease. Exp Mol Med (2009) 0.92
High throughput screening for inhibitors of alpha-galactosidase. Curr Chem Genomics (2010) 0.92
Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels. Mol Genet Metab (2008) 0.91
Chemical chaperone and inhibitor discovery: potential treatments for protein conformational diseases. Perspect Medicin Chem (2007) 0.90
Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy. Proc Natl Acad Sci U S A (2013) 0.89
Beta-galactosidase deficiency: an approach to chaperone therapy. J Inherit Metab Dis (2006) 0.88
Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease. J Biochem (2010) 0.86
Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem (2009) 0.85
Protein quality control: the who's who, the where's and therapeutic escapes. Histochem Cell Biol (2007) 0.85
Fabry disease - current treatment and new drug development. Curr Chem Genomics (2010) 0.85
A rapid and sensitive method for measuring N-acetylglucosaminidase activity in cultured cells. PLoS One (2013) 0.84
Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism. J Inherit Metab Dis (2010) 0.84
Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study. Ann Clin Transl Neurol (2016) 0.81
Update on treatment of lysosomal storage diseases. Acta Myol (2007) 0.81
Chaperone therapy for Krabbe disease: potential for late-onset GALC mutations. J Hum Genet (2015) 0.81
Emerging novel concept of chaperone therapies for protein misfolding diseases. Proc Jpn Acad Ser B Phys Biol Sci (2014) 0.80
A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther (2013) 0.79
Structural basis of pharmacological chaperoning for human β-galactosidase. J Biol Chem (2014) 0.79
Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease. J Inherit Metab Dis (2011) 0.78
Current themes in molecular pediatrics: molecular medicine and its applications. Ital J Pediatr (2010) 0.78
Fluorous iminoalditols: a new family of glycosidase inhibitors and pharmacological chaperones. Chembiochem (2010) 0.77
Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy. Mol Genet Metab (2012) 0.77
Gene therapy for GM1 gangliosidosis: challenges of translational medicine. Ann Transl Med (2015) 0.75
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet (2000) 4.27
Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med (1999) 3.11
Quantitative isolation of total glycosphingolipids from animal cells. J Lipid Res (1971) 2.29
Gangliosides of human, bovine, and rabbit plasma. J Lipid Res (1972) 1.99
Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science (1997) 1.70
The use of Sep-Pak C18 cartridges during the isolation of gangliosides. J Neurochem (1980) 1.62
Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci U S A (1999) 1.53
Accumulation of cholera toxin and GM1 ganglioside in the early endosome of Niemann-Pick C1-deficient cells. Proc Natl Acad Sci U S A (2001) 1.28
Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins. Hum Genet (1995) 1.14
An improved thin-layer chromatographic method for urinary oligosaccharide screening. Clin Chim Acta (1979) 1.08
Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. Biochem Biophys Res Commun (1995) 1.07
Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis. Biochem J (2000) 1.02
Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci (2003) 1.00
Galactonojirimycin derivatives restore mutant human beta-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse. Brain Dev (2001) 0.95
Human glucocerebrosidase: heterologous expression of active site mutants in murine null cells. Glycobiology (2000) 0.94
Galactosialidosis (beta-galactosidase-neuraminidase deficiency): a possible role of serine-thiol proteases in the degradation of beta-galactosidase molecules. Clin Chim Acta (1982) 0.94
Beta-galactosidase-deficient mouse as an animal model for GM1-gangliosidosis. Glycoconj J (1997) 0.93
Aggregation of the inactive form of human alpha-galactosidase in the endoplasmic reticulum. Biochem Biophys Res Commun (1996) 0.92
Mutational analysis of TSC1 and TSC2 genes in Japanese patients with tuberous sclerosis complex. J Hum Genet (1999) 0.89
Structural features of normal and mutant human lysosomal glycoside hydrolases deduced from bioinformatics analysis. Hum Mol Genet (2000) 0.89
Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives. Bioorg Med Chem (2002) 0.87
Sites and temporal changes of gangliosides GM1/GM2 storage in the Niemann-Pick disease type C mouse brain. Brain Dev (2001) 0.86
Chemical modification of beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivatives. Bioorg Med Chem (1998) 0.86
Amniotic tissue transplantation as a trial of treatment in some lysosomal storage diseases. J Inherit Metab Dis (1985) 0.82
Bone marrow transplantation in canine GM1 gangliosidosis. Clin Genet (1990) 0.82
Development of lysosomal storage in mice with targeted disruption of the beta-galactosidase gene: a model of human G(M1)-gangliosidosis. Brain Dev (2001) 0.82
Alpha-galactosidase transgenic mouse: heterogeneous gene expression and posttranslational glycosylation in tissues. Glycoconj J (1998) 0.80
Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet (2003) 7.98
Mapping human genetic diversity in Asia. Science (2009) 7.40
Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol (2004) 7.17
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol (2006) 6.55
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (2013) 5.03
The dynamic genome of Hydra. Nature (2010) 4.00
Phylogenetic analysis of the complete genome of 18 Norwalk-like viruses. Virology (2002) 3.79
Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1. Nat Cell Biol (2006) 3.19
Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00
Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature (2010) 2.91
Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A (2008) 2.87
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol (2003) 2.86
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med (2006) 2.81
Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg (2003) 2.80
Conversion of channelrhodopsin into a light-gated chloride channel. Science (2014) 2.56
Effects of cyclodextrin in two patients with Niemann-Pick Type C disease. Mol Genet Metab (2012) 2.52
Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) (2002) 2.51
Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology (2013) 2.36
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol (2004) 2.24
Fabry disease in childhood. J Pediatr (2004) 2.20
Relationship between cold temperature and cardiovascular mortality, with assessment of effect modification by individual characteristics: Ibaraki Prefectural Health Study. Circ J (2013) 2.15
The origin and evolution of porcine reproductive and respiratory syndrome viruses. Mol Biol Evol (2005) 2.09
Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity (2010) 2.09
Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol (2005) 2.07
A large variation in the rates of synonymous substitution for RNA viruses and its relationship to a diversity of viral infection and transmission modes. Mol Biol Evol (2004) 2.07
The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts. Nucleic Acids Res (2007) 2.07
Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem (2006) 2.03
Reliabilities of identifying positive selection by the branch-site and the site-prediction methods. Proc Natl Acad Sci U S A (2009) 1.94
Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol (2011) 1.89
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol (2008) 1.88
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant (2005) 1.84
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology (2009) 1.83
Genetic polymorphisms of alcohol and aldehyde dehydrogenases and glutathione S-transferase M1 and drinking, smoking, and diet in Japanese men with esophageal squamous cell carcinoma. Carcinogenesis (2002) 1.81
Impact of earthquakes on Takotsubo cardiomyopathy. JAMA (2005) 1.81
Transcriptional interferences in cis natural antisense transcripts of humans and mice. Genetics (2007) 1.79
Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlation. Hum Mutat (2004) 1.76
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol (2008) 1.76
Complete genetic correction of ips cells from Duchenne muscular dystrophy. Mol Ther (2009) 1.74
Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology (2005) 1.71
Organic anion transporters play an important role in the uptake of p-cresyl sulfate, a uremic toxin, in the kidney. Nephrol Dial Transplant (2011) 1.69
Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci (2008) 1.67
Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol (2004) 1.66
The neutral theory of molecular evolution in the genomic era. Annu Rev Genomics Hum Genet (2010) 1.65
Role of sialic acid and complex carbohydrate biosynthesis in biofilm formation by nontypeable Haemophilus influenzae in the chinchilla middle ear. Infect Immun (2005) 1.65
Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol (2006) 1.65
Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology (2011) 1.63
The important role of operations in the management of anaplastic thyroid carcinoma. Surgery (2002) 1.61
Hyperbaric oxygen therapy for air embolism complicating CT-guided needle biopsy of the lung. AJR Am J Roentgenol (2004) 1.60
Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol (2007) 1.59
Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol (2008) 1.59
Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J (2013) 1.57
Quality of life of oral cancer patients after low-dose-rate interstitial brachytherapy. Int J Radiat Oncol Biol Phys (2009) 1.56
Unsuccessful internal defibrillation in Brugada syndrome: focus on refractoriness and ventricular fibrillation cycle length. J Cardiovasc Electrophysiol (2005) 1.55
Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res (2005) 1.54
Multiple Wnts are involved in Hydra organizer formation and regeneration. Dev Biol (2009) 1.54
Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol (2012) 1.53
Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod (2006) 1.52
Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice. J Neuropathol Exp Neurol (2005) 1.52
Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve (2003) 1.51
Skin-impedance in Fabry Disease: a prospective, controlled, non-randomized clinical study. BMC Neurol (2008) 1.51
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg (2007) 1.51
Anti-Ku antibody-positive scleroderma-dermatomyositis overlap syndrome developing Graves' disease and immune thrombocytopenic purpura. Intern Med (2002) 1.49
Blockade of sarcolemmal TRPV2 accumulation inhibits progression of dilated cardiomyopathy. Cardiovasc Res (2013) 1.49
Stabilization of exocytosis by dynamic F-actin coating of zymogen granules in pancreatic acini. J Biol Chem (2004) 1.49
Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol (2003) 1.46
Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol (2002) 1.46
Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol (2004) 1.46
A randomized clinical study of tea catechin inhalation effects on methicillin-resistant Staphylococcus aureus in disabled elderly patients. J Am Med Dir Assoc (2005) 1.46
Rapid-onset primary biliary cirrhosis resembling drug-induced liver injury. Intern Med (2005) 1.46
Pheochromocytoma of the urinary bladder without typical symptoms. Int J Urol (2003) 1.46
Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load. J Gastroenterol (2003) 1.45
Possible false-negative results on therapeutic drug monitoring of phenytoin using a particle enhanced turbidimetric inhibition immunoassay in a patient with a high level of IgM. Ther Drug Monit (2014) 1.44
Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy. J Gastroenterol (2002) 1.43
Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models. J Control Release (2012) 1.43
Pediatric Fabry disease. Pediatrics (2005) 1.43
Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol (2004) 1.42
Linoleic acid attenuates endothelium-derived relaxing factor production by suppressing cAMP-hydrolyzing phosphodiesterase activity. Circ J (2013) 1.41
ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics (2010) 1.41
Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos (2004) 1.41
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. J Gastroenterol (2004) 1.41
Mortality and risk factors for late deaths in tetralogy of Fallot: the Japanese Nationwide Multicentric Survey. Cardiol Young (2002) 1.41
Drug-induced Liver Injury with HHV-6 Reactivation. Intern Med (2015) 1.39
Preexcitation unmasks J waves: 2 cases. J Electrocardiol (2010) 1.39
Mental retardation, spasticity, basal ganglia calcification, cerebral white matter lesions, multiple endocrine defects, telangiectasia and atrophic skin: a new syndrome? Brain Dev (2007) 1.39
Progressive leukoencephalopathy with intracranial calcification, congenital deafness, and developmental deterioration. Am J Med Genet A (2011) 1.38
Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squamous cell carcinoma in Japanese men. Cancer Epidemiol Biomarkers Prev (2003) 1.36
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol (2012) 1.35
Cyclin-dependent kinase 5 activity regulates pain signaling. Proc Natl Acad Sci U S A (2006) 1.34
Evola: Ortholog database of all human genes in H-InvDB with manual curation of phylogenetic trees. Nucleic Acids Res (2007) 1.32
Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1. Proc Natl Acad Sci U S A (2006) 1.31
Novel calmodulin mutations associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet (2014) 1.27
PprA: a novel protein from Deinococcus radiodurans that stimulates DNA ligation. Mol Microbiol (2004) 1.27
A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene. Mol Ther (2008) 1.27
Increased incidence of transient left ventricular apical ballooning (so-called 'Takotsubo' cardiomyopathy) after the mid-Niigata Prefecture earthquake. Circ J (2006) 1.26
Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol (2005) 1.26